Evidence Hub

A case of type 4 advanced gastric cancer with aplastic anemia successfully treated with neoadjuvant chemotherapy and surgical resection

Moon JH, Fujiwara Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M et al.

Gan to kagaku ryoho. Cancer & chemotherapy, 2010

Abstract

We have experienced a case of Type 4 advanced gastric cancer with aplastic anemia, which had been treated with S-1 and intra-peritoneal docetaxcel combination chemotherapy followed by surgery. Fifteen years ago, a 51-year-old woman was diagnosed as aplastic anemia but she ignored any treatment due to no symptoms. A Type 4 advanced gastric cancer was detected with a chief complaint of stomach heaviness in December 2009. Peritoneal lavage cytology was performed before treatment and showed positive peritoneal dissemination. Two courses of S-1 and intra-peritoneal docetaxcel combination chemotherapy was administered but no serious side effects occurred during the therapy. Total gastrectomy with D2 lymph node dissection was successfully undergone. The final stage was ypT4aN3H0M0P1, Stage IV. It appeared that S-1 and intraperitoneal docetaxcel combination chemotherapy was a safe regimen for a patient with aplastic anemia in our case.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free